Archana Mishra Agarwal, MD

Associate Professor, University of Utah School of Medicine

Specialties

• RBC membrane and enzyme disorders
• Hemoglobinopathies/thalassemia
• Molecular hematology

Education

• Medical Degree—Delhi University
• Residency—Anatomic and Clinical Pathology, University of Utah School of Medicine
• Fellowship—Hematopathology, University of Utah School of Medicine
• Fellowship—Molecular Genetic Pathology, University of Utah School of Medicine

Certification/Affiliations

• American Board of Pathology (Anatomic Pathology and Clinical Pathology, Hematology, Molecular Genetic Pathology)

Research Interests

• Red-cell enzymopathies
• Hemoglobinopathies
• Molecular hematopathology

Recent Publications

• He L, et al. Diagnosis of hemoglobinopathy and β-thalassemia by 21 tesla fourier transform ion cyclotron resonance MS and MS/MS of hemoglobin from blood. Clin Chem. 2019 Aug;65(8):98–95. Epub.
• Rets A, et al. Molecular diagnostic update in hereditary hemolytic anemia. Int J Lab Hematol. 2019. May; 41(Suppl 1):95–101.
• Hahn A, et al. Predicting response to vascular endothelial growth factor tyrosine kinase inhibitors (VEGFTKIs) in metastatic clear cell renal cell carcinoma (mccRCC): differences in RNA expression using nCounter® PanCancer Pathways Panel. PLOS ONE. Jan 25;14(1).
• Bahr TM, et al. The Neonatal Acute Bilirubin Encephalopathy Registry (NABER): Background, Aims, and Protocol. Neonatology. 2019;115(3):242–6.
• Archana M Agarwal. Ankyrin Mutations in Hereditary Spherocytosis. Commentary. Acta Haematologica. 2019 Jan 2;141(2):63–4.
• Polega J, Stumph J, Agarwal A, et al. Novel mutation in spta1 gene associated with severe hemolytic anemia. J Pediatr Neonatal Care. 2018;8(5):250–3.
• Bianchi P, et al. Addressing the diagnostic gaps in pyruvate kinase (PK) deficiency: consensus recommendation on the diagnosis of PK deficiency. Am J Hematol. 2019 Jan;94(1):149–61.
• Christensen RD, et al. Acute neonatal bilirubin encephalopathy in the State of Utah 2009–2018. Blood Cells Mol Dis. 2018 Sep;72:10–3.
• Christensen RD, et al. Three novel spectrin variants in jaundiced neonates. Clin Pediatr (Phila). 2018 Jan;57(1):19–26.
• Bailey EB, et al. Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract. 2018 Apr;24(3):190–7.
• He L, et al. Diagnosis of hemoglobinopathy and β-thalassemia by 21 Tesla fourier transform ion cyclotron resonance MS and MS/MS of hemoglobin from blood. Clin Chem. 2019 Aug;65(8):986–94.
• Rets A, et al. Molecular diagnostic update in hereditary hemolytic anemia and neonatal hyperbilirubinemia. Int J Lab Hematol. 2019 May;41(Suppl 1):95–101.
• Hahn A, et al. Predicting response to vascular endothelial growth factor tyrosine kinase inhibitors (VEGFTKIs) in metastatic clear cell renal cell carcinoma (mccRCC): differences in RNA expression using nCounter® PanCancer Pathways Panel. PLOS ONE. Jan 25;14(1). 
• Bahr TM, et al. The Neonatal Acute Bilirubin Encephalopathy Registry (NABER): Background, Aims, and Protocol. Neonatology. 2019;115(3):242–6.
• Agarwal AM. Ankyrin Mutations in Hereditary Spherocytosis. Acta Haematologica. 2019;141(2):63–4
• Polega J, et al. Novel mutation in spta1 gene associated with severe hemolytic anemia. J Pediatr Neonatal Care. 2018;8(5):250–3.
• Bianchi P, et al. Addressing the diagnostic gaps in pyruvate kinase (PK) deficiency: Consensus Recommendation on the diagnosis of PK deficiency. Am J Hematol. 2019 Jan;94(1):149–61
• Christensen RD, et al. Acute neonatal bilirubin encephalopathy in the State of Utah 2009-2018. Blood Cells Mol Dis. 2018 Sep;72:10–3.
• Christensen RD, et al. Three novel spectrin variants in jaundiced neonates. Clin Pediatr (Phila). 2018 Jan;57(1):19–26
• Bailey EB, et al. Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract. 2018 Apr;24(3):190–7.
• Hahn AW, et al. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget. 2017 May 16;8(20):33614–20.
• Davis KL, Agarwal AM, Verma AR. Checkpoint inhibition in pediatric hematologic malignancies. Pediatric Hem Onc. 2017 Sep-Oct;34(6–7):379–94.
• Kuzman JA, et al. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol. 2017 Jan 5;17(1):1.
• Luedeke M, et al. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum Mol Genet. 2016 Dec 15;25(24):5490–9.
• Gill DM, et al. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience. 2016 Sep 29;10:676.
• Reading NS, et al. Loss of major DNase I hypersensitive sites in duplicated β-globin gene cluster incompletely silences HBB gene expression. Hum Mutat. 2016 Nov;37(11):1153–6.
• Christensen RD, et al. Siblings with severe pyruvate kinase deficiency and a complex genotype. Am J Med Genet A. 2016 Sep;170(9):2449–52.
• Agarwal AM, et al. Clinical utility of next-generation sequencing in the diagnosis of hereditary hemolytic anemias. Br J Haematol. 2016 Sep;174(5):806–14.
• Stenehjem DD, et al. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother. 2016 Aug;65(8):941–9.
• Patel SB, et al. Everolimus versus temsirolimus in metastatic renal cell carcinoma after progression with previous systemic therapies. Clin Genitourin Cancer. 2016 Apr;14(2):153–9.
• Archana M Agarwal, et al. Robert Christensen. Improved harmonization of Eosin -5-maleimide binding test across different instruments and age groups. Cytometry Part B Clinical Cytometry. 2015 Sep 18;90(6):512–6.
• Nussenzveig RH, Pham Ha T, Perkins SL, Prchal JT, Agarwal AM, Salama ME. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden. Leuk Lymphoma. 2016;57(6):1429–35.
• Bailey EB, et al. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer. 2015 Jun;13(3):e131–7.
• Christensen R, et al. Prolonged phototherapy needed for a neonate with four mutations in genes involved in bilirubin production and metabolism. J Neonatal Perinatal Med. 2015 March 10.
• Tantravahi SK, et al. Survival outcomes and tumor IMP3 expression in patients with sarcomatoid metastatic renal cell carcinoma. J Oncol. 2015; 2015:181926.
• Greene D, et al. Advances in detection of Hemoglobinopathies. Clin Chim Acta. 2015 Jan 15;439:50–7.